Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94996Research ArticlePatients with chronic obstructive pulmonary disease: analysis of actual clinical practiceVizelA. Alordara@inbox.ruSalakhovaI. N-VizelI. Yu-VafinaA. R-ShakirovaG. R-KudriavtsevaE. Z-Kazan State Medical University of the Ministry of Health of the Russian FederationRepublican Clinical Hospital of the Ministry of Health of the Republic of TatarstanCity Clinical Hospital №1615032018203353928122021Copyright © 2018, Consilium Medicum2018Chronic obstructive pulmonary disease (COPD) remains a disease whose global prevalence is not decreasing, and mortality is increasing. Over the past 10 years, the position of the global initiative GOLD classification and treatment COPD three times changed. The aim of the work is to assess the distribution of COPD patients according to different criteria, peculiarities of their treatment and adherence to treatment. Material and methods. 125 patients with COPD in hospital - 123 (98.4%) men and 2 (1.6%) women with an average age of 64.9±0.7 (8.2) years were examined. All patients underwent physical examination, a survey on standardized questionnaires CAT and mMRC and spirography. Results. According to GOLD 2007 classification, patients were distributed as follows: GOLD I - 6.4%, GOLD II - 29.6%, GOLD III - 43.2%, GOLD IV - 20.8%. According to the ABCD GOLD 2011 classification, 4% of patients were classified as type C and 96% as type D, and 3.2, 11.2, 0.8 and 84.8%, respectively, in ABCD GOLD 2017 redistribution. Such factors as hospitalization, changed the distribution of the patients according to groups ABCD. Among the respondents 93.6% received short - acting bronchodilators, 63.2% - long-acting bronchodilators, inhalation steroids with long-acting bronchodilators - 58.4%. 27,2% of patients were completely complementary, 72.8% of patients were well trained by the medical worker to correct use of the inhaler. Patients among all drugs preferred short-acting bronchodilators and dosing aerosol inhalers, would like to use them only on demand. The worst time of the day the majority of patients called morning. Conclusion. The study reflects the dynamism in the diagnosis and treatment of COPD, the change of priorities from clinical physiology to anamnetic data. Identified key areas that will improve the quality of treatment of patients with COPD in the studied region - the increased commitment of physicians national clinical guidelines and improving patient adherence to doctor's prescriptions.chronic obstructive pulmonary diseasetreatmentclinical recommendationstherapeutic cooperationхроническая обструктивная болезнь легкихлечениеклинические рекомендациитерапевтическое сотрудничество[Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): 2018 report. 2018. www.coldcopd.prg][Чучалин А.Г., Авдеев C.H., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 24 (3): 15-36.][Вафин А.Ю., Визель А.А., Шерпутовский В.Г. и др. Заболевания органов дыхания в Республике Татарстан: многолетний эпидемиологический анализ. Вестн. соврем. клин. медицины. 2016; 9 (1): 24-31.][Визель А.А., Салахова И.Н., Вафина А.Р. и др. Клиническая характеристика больных хронической обструктивной болезнью легких, находившихся в пульмонологических отделениях города Казани. Consilium Medicum. 2017; 19 (11.1. Болезни органов дыхания): 21-4.][Обновленный проект клинических рекомендаций. Хроническая обструктивная болезнь легких. http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomen-datsii][Cabrera López C, Casanova Macario C, Marín Trigo J.M. et al. Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on grouping and outcomes. Am J Respir Crit Care Med 2018; 197 (4): 463-9.][Kaplan A, Thomas M. Screening for COPD: the gap between logic and evidence. Eur Respir Rev 2017; 26 (143); pii 160113.][Jones P.W., Beeh K.M., Chapman K.R. et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189 (3): 250-5.][Garc Da Garc Da S, Carazo Fern Ondez L, Juan Garc Da J, Naveiro Rilo J.C. Chronic obstructive pulmonary disease in real life. LEONPOC study. Aten Primaria 2017; 49 (10): 603-10.]